全文获取类型
收费全文 | 536篇 |
免费 | 23篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 24篇 |
妇产科学 | 11篇 |
基础医学 | 65篇 |
口腔科学 | 16篇 |
临床医学 | 50篇 |
内科学 | 110篇 |
皮肤病学 | 4篇 |
神经病学 | 21篇 |
特种医学 | 17篇 |
外科学 | 96篇 |
综合类 | 12篇 |
一般理论 | 2篇 |
预防医学 | 52篇 |
眼科学 | 8篇 |
药学 | 34篇 |
中国医学 | 5篇 |
肿瘤学 | 26篇 |
出版年
2023年 | 2篇 |
2022年 | 18篇 |
2021年 | 30篇 |
2020年 | 19篇 |
2019年 | 29篇 |
2018年 | 19篇 |
2017年 | 11篇 |
2016年 | 22篇 |
2015年 | 20篇 |
2014年 | 15篇 |
2013年 | 28篇 |
2012年 | 39篇 |
2011年 | 41篇 |
2010年 | 20篇 |
2009年 | 21篇 |
2008年 | 30篇 |
2007年 | 30篇 |
2006年 | 31篇 |
2005年 | 26篇 |
2004年 | 22篇 |
2003年 | 5篇 |
2002年 | 21篇 |
2001年 | 8篇 |
2000年 | 8篇 |
1999年 | 4篇 |
1998年 | 1篇 |
1997年 | 2篇 |
1996年 | 1篇 |
1995年 | 1篇 |
1994年 | 2篇 |
1993年 | 5篇 |
1992年 | 3篇 |
1991年 | 3篇 |
1990年 | 1篇 |
1989年 | 1篇 |
1988年 | 2篇 |
1987年 | 3篇 |
1986年 | 2篇 |
1985年 | 2篇 |
1984年 | 1篇 |
1980年 | 2篇 |
1979年 | 1篇 |
1978年 | 3篇 |
1977年 | 1篇 |
1975年 | 2篇 |
1974年 | 1篇 |
1972年 | 1篇 |
1940年 | 1篇 |
排序方式: 共有561条查询结果,搜索用时 265 毫秒
1.
2.
Wani T Kakru DK Shaheen R Nazir A Lone R Shakeel S Shah A 《Indian journal of pathology & microbiology》2004,47(1):76-77
Endocarditis is a rare complication of typhoid fever. We report a case in which Salmonella enterica serotype typhi was isolated from a case of endocarditis. The isolate was resistant to ampicillin, chloramphenicol and ciprofloxacin but sensitive to ceftriaxone, amikacin and gentamicin. 相似文献
3.
Nazir Ahmad Tahmina Ruhi 《Indian journal of otolaryngology and head and neck surgery》1994,46(2):96-100
BAEPS are coming up as an important investigatory tool in the hands of present clinicians and have a diagnostic and prognostic significance. The present study was carried on 25 patients. BAEPS were recorded at the time of admission and analysed. Absent BAEPS were associated with high mortality. Abnormal BAEPS were seen in infective and CVA group. Followup BAEPS showed no change in those patients who died. 相似文献
4.
Jonathan D. Adachi Professor Everett J. Sargeant Professor Margaret A. Sagle Associate Professor David Lament Assistant Professor Paul D. Fawcett Obstetrician Gynaecologist William G. Bensen Associate Clinical Professor Matthew McQueen Chief Director Professor Darius J. Nazir Clinical Chemist Associate Professor Charles H. Goldsmith Professor Head 《BJOG : an international journal of obstetrics and gynaecology》1997,104(1):64-70
Objective To assess the effects of medroxyprogesterone acetate on bone density in women who have had a hysterectomy
Design Randomised, double-blind, placebo-controlled trial of medroxyprogesterone acetate 10 mg, 20 mg or placebo as an adjunct to oestrogen therapy.
Participants One hundred and twenty-three women, aged 18 to 45 years and currently receiving daily oestrogen, who presented at a university-based rheumatology practice.
Interventions The women were randomly assigned to receive either medroxyprogesterone acetate 10 mg, 20 mg or placebo daily beginning on day 15 of each month for one year. Forty-one women were randomised into each group.
Main outcome measure The primary outcome measurement was the percentage of change from baseline in bone mineral density of the lumbar spine (L2–L4). Secondary outcome measures included differences in femoral neck bone density, cholesterol and triglyceride levels between groups.
Results At one year, change in bone mineral density did not differ between either the treatment or placebo groups. Medroxyprogesterone acetate 20 mg and 10 mg led to statistically significant reductions in very low density lipoprotein cholesterol, total triglycerides, and very low density lipoprotein triglycerides when compared with placebo. Medroxyprogesterone acetate 20 mg also led to a statistically significant reduction in high density lipoprotein cholesterol, high density lipo-protein-2 cholesterol, and high density lipoprotein-2 triglycerides.
Conclusions Medroxyprogesterone acetate at either dose as an adjunct to oestrogen did not improve bone mineral density at one year when compared with placebo. Medroxyprogesterone acetate 10 mg may not adversely affect lipids. Medroxyprogesterone acetate 20 mg, however, did reduce high density lipoprotein cholestrol and therefore may increase cardiovascular risk. 相似文献
Design Randomised, double-blind, placebo-controlled trial of medroxyprogesterone acetate 10 mg, 20 mg or placebo as an adjunct to oestrogen therapy.
Participants One hundred and twenty-three women, aged 18 to 45 years and currently receiving daily oestrogen, who presented at a university-based rheumatology practice.
Interventions The women were randomly assigned to receive either medroxyprogesterone acetate 10 mg, 20 mg or placebo daily beginning on day 15 of each month for one year. Forty-one women were randomised into each group.
Main outcome measure The primary outcome measurement was the percentage of change from baseline in bone mineral density of the lumbar spine (L2–L4). Secondary outcome measures included differences in femoral neck bone density, cholesterol and triglyceride levels between groups.
Results At one year, change in bone mineral density did not differ between either the treatment or placebo groups. Medroxyprogesterone acetate 20 mg and 10 mg led to statistically significant reductions in very low density lipoprotein cholesterol, total triglycerides, and very low density lipoprotein triglycerides when compared with placebo. Medroxyprogesterone acetate 20 mg also led to a statistically significant reduction in high density lipoprotein cholesterol, high density lipo-protein-2 cholesterol, and high density lipoprotein-2 triglycerides.
Conclusions Medroxyprogesterone acetate at either dose as an adjunct to oestrogen did not improve bone mineral density at one year when compared with placebo. Medroxyprogesterone acetate 10 mg may not adversely affect lipids. Medroxyprogesterone acetate 20 mg, however, did reduce high density lipoprotein cholestrol and therefore may increase cardiovascular risk. 相似文献
5.
Kimberly K. Engelman PhD ; Edward F. Ellerbeck MD MPH ; Denise Perpich MPH ; Niaman Nazir MBBS MPH ; Kevin McCarter PhD ; Jasjit S. Ahluwalia MD MPH 《The Journal of rural health》2004,20(1):36-42
CONTEXT: Breast cancer screening rates are lower in rural communities. Although studies have addressed barriers to mammography for rural residents, physician practice barriers have received less attention. PURPOSE: Controlled clinical trials have shown that the use of office reminder systems in primary care practices is related to increased clinical care rates. Therefore, we compared office systems use in primary care practices located in rural and urban communities and assessed the impact of these systems on rural-urban differences in mammography utilization. METHODS: We identified female Kansas Medicare beneficiaries aged 65 to 79 from Medicare claims data (N = 24,030) and determined which beneficiaries received a mammogram between April 1, 1999, and March 31, 2001. We linked beneficiaries to their primary care providers and obtained surveys from 180 primary care practices on their use of office reminder systems. FINDINGS: Mammography rates ranged from 20% to 92% (mean = 65%) among the 180 practices. Flowsheets with a mammography prompt were used by 33% of the practices, 38% utilized nonphysician staff to identify women due for mammograms, and 15% used computerized reminder systems. Urban practices used flowsheets more often than rural practices (44% versus 16%, P < 0.001). A multivariable regression model demonstrated higher mammography rates in urban practices, group practices, and practices using mammography flowsheets. CONCLUSIONS: Despite success in randomized controlled trials, reminder systems are not used often by primary care providers and are used even less often in rural compared to urban practices. Consistent implementation may be a major barrier to the successful adaptation of flowsheets by primary care offices. 相似文献
6.
7.
8.
9.
10.
Cari Levy MD PhD Sheryl Zimmerman PhD Vincent Mor PhD David Gifford MD Sherry A. Greenberg PhD RN GNP-BC Juliet Holt Klinger MA Cathy Lieblich MA Sunny Linnebur PharmD Angie McAllister BA Arif Nazir MD Douglas Pace NHA Robyn Stone PhD Barbara Resnick PhD RN CRNP Philip D. Sloane MD Joseph Ouslander MD Joseph E. Gaugler PhD 《Journal of the American Geriatrics Society》2022,70(3):709-717
Randomized controlled trials are considered the most rigorous research design in efficacy and effectiveness research; however, such trials present numerous challenges that limit their applicability in real-world settings. As a consequence, pragmatic trials are increasingly viewed as a research design that overcomes some of these barriers with the potential to produce findings that are more reproducible. Although pragmatic methodology in long-term care is receiving increasing attention as an approach to improve successful dissemination and implementation, pragmatic trials present complexities of their own. To address these complexities and related issues, experts with experience conducting pragmatic trials, developing nursing home policy, participating in advocacy efforts, and providing clinical care in long-term care settings participated in a virtual consensus conference funded by the National Institute on Aging in Spring 2021. Participants identified 4 cross-cutting principles key to dissemination and implementation of pragmatic trial interventions: (1) stakeholder engagement, (2) diversity and inclusion, (3) organizational strain and readiness, and (4) learn from adaptations. Participants emphasized that implementation processes must be grounded in the perspectives of the people who will ultimately be responsible for implementing the intervention once it is proven to be effective. In addition, messaging must speak to long-term care staff and all others who have a stake in its outcomes. Although our understanding of dissemination and implementation strategies remains underdeveloped, this article is designed to guide long-term care researchers and community providers who are increasingly aware of the need for pragmatism in disseminating and implementing evidence-based care interventions. 相似文献